How should I manage the medications of a 52‑year‑old female with panic‑type anxiety, binge‑eating disorder, ADHD, and depression who is taking Vyvanse 30 mg daily, lorazepam (Ativan) 1.5 mg three times daily, and zolpidem (Ambien) 6.5 mg nightly and wishes to remain on controlled substances?

Prioritize Tapering Benzodiazepines and Z-Drugs While Optimizing Evidence-Based Treatments

Your patient's current regimen requires urgent modification: the high-dose, chronic benzodiazepine (lorazepam 4.5 mg/day) and zolpidem pose significant risks for dependence, cognitive impairment, and falls in a 52-year-old woman, and should be gradually tapered while optimizing her Vyvanse for both ADHD and binge eating disorder, and adding an SSRI for panic disorder and depression.

Immediate Medication Strategy

1. Continue and Optimize Vyvanse

• Maintain Vyvanse 30 mg for both ADHD and binge eating disorder 1, 2
• The APA guideline suggests lisdexamfetamine (Vyvanse) for adults with binge eating disorder who prefer medication or have not responded to psychotherapy alone 1
• Vyvanse is FDA-approved for both ADHD and moderate-to-severe binge eating disorder, with doses ranging 30-70 mg daily 2
• Monitor blood pressure, heart rate, and psychiatric symptoms (anxiety, mood changes) given her panic disorder 2
• Important caveat: Screen for cardiac disease before continuing stimulant therapy; avoid in patients with serious cardiac conditions 2

2. Add an SSRI for Panic Disorder and Depression

• Start fluoxetine 20 mg daily (or paroxetine 20 mg if fluoxetine not tolerated)
• SSRIs are first-line for panic disorder with strong evidence for response and remission 3, 4
• Fluoxetine specifically shows efficacy for anxiety in both anorexia nervosa and bulimia nervosa 5, and may help her binge eating disorder
• For panic disorder, fluoxetine and paroxetine demonstrate stronger evidence than sertraline 3
• Titrate to therapeutic doses: fluoxetine 20-60 mg or paroxetine 20-60 mg over 4-8 weeks
• Monitor for serotonin syndrome when combining with Vyvanse, though risk is low at therapeutic doses 2

3. Initiate Slow Benzodiazepine Taper

This is the most critical intervention for long-term morbidity and mortality.

• Lorazepam 4.5 mg/day is a high chronic dose associated with:
  • Cognitive impairment
  • Fall risk (especially concerning in a 52-year-old woman approaching higher fracture risk)
  • Dependence and withdrawal complications
  • Paradoxical anxiety worsening

Taper protocol:

• Wait 4-6 weeks after starting SSRI to allow therapeutic effect before beginning taper
• Reduce by 0.25-0.5 mg every 1-2 weeks (approximately 10% reduction per step)
• Consider converting to longer-acting clonazepam or diazepam for smoother taper if withdrawal symptoms are problematic
• Total taper duration: 3-6 months minimum
• Common pitfall: Tapering too quickly leads to rebound anxiety, seizures, and treatment failure

4. Discontinue Zolpidem

• Zolpidem (Ambien) 6.5 mg is a controlled substance with dependence risk 6
• The FDA label recommends 6.25 mg for women due to slower clearance and next-day impairment risk 6
• Taper approach: Reduce by 1/4 tablet every 1-2 weeks while implementing sleep hygiene
• Alternative non-controlled options after discontinuation:
  • Trazodone 25-100 mg at bedtime
  • Mirtazapine 7.5-15 mg at bedtime (also helps depression/anxiety)
  • Cognitive behavioral therapy for insomnia (CBT-I) is first-line

Addressing Her Desire to Stay on Controlled Substances

Your patient states she "does want to be on controlled substances"—I interpret this as wanting to REMAIN on them, which requires direct counseling:

• Explain that chronic benzodiazepine use actually worsens panic disorder long-term by preventing natural anxiety habituation
• Benzodiazepines ranked highest for short-term tolerability but are NOT recommended as first-line due to dependency and long-term risks 3, 4
• SSRIs provide superior long-term outcomes for panic disorder without dependence risk 4
• Vyvanse can remain as it treats two of her conditions (ADHD and binge eating) with legitimate medical indication 1, 2

Monitoring Plan

Weeks 0-4:

• Start fluoxetine 20 mg daily
• Continue current doses of Vyvanse and lorazepam
• Monitor for serotonin syndrome symptoms (agitation, confusion, tremor, hyperthermia)
• Check blood pressure and heart rate

Weeks 4-6:

• Assess SSRI response for panic symptoms
• Titrate fluoxetine to 40 mg if partial response
• Begin lorazepam taper if SSRI showing benefit

Weeks 6-24:

• Continue slow lorazepam taper
• Begin zolpidem taper around week 12
• Monitor for withdrawal symptoms (rebound anxiety, insomnia, tremor, seizures)
• Adjust SSRI dose up to 60 mg if needed for panic disorder

Ongoing:

• Reassess binge eating frequency and ADHD symptoms
• Consider increasing Vyvanse to 50-70 mg if inadequate response 2
• Monitor weight, as Vyvanse causes appetite suppression 2

Critical Warnings

• Never abruptly discontinue benzodiazepines at this dose—seizure risk is significant
• Screen for cardiac disease before continuing stimulants 7, 2
• Watch for psychiatric adverse reactions with Vyvanse (new mania, psychosis) 2
• The combination of panic disorder and stimulants requires careful monitoring, though stimulants can be used in anxiety disorders 7
• Growth suppression is not a concern in adults, but monitor weight loss carefully given binge eating disorder 2

Evidence Quality Note

The recommendation to taper benzodiazepines is based on high-quality evidence showing they are not first-line for panic disorder despite short-term efficacy 3, 4. The SSRI recommendation is supported by multiple high-quality systematic reviews and meta-analyses 3, 4. Vyvanse for binge eating disorder is supported by APA guidelines 1 and FDA approval 2.